NCT06212648View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

253

Participants

Timeline

Start Date

March 25, 2022

Primary Completion Date

November 27, 2022

Study Completion Date

January 27, 2023

Conditions
HypertensionEssential Hypertension
Interventions
DRUG

SPC1001 High

"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."

DRUG

SPC1001 Mid1

"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."

DRUG

SPC1001 Mid2

"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."

DRUG

SPC1001 Low

"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."

DRUG

SPC3001

"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."

DRUG

SPC4001

"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."

DRUG

SPC4002

"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."

DRUG

Placebo

"Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks."

Trial Locations (1)

06135

CHA Gangnam Medical Center, CHA University, Seoul

All Listed Sponsors
lead

Shin Poong Pharmaceutical Co. Ltd.

INDUSTRY